<DOC>
	<DOCNO>NCT02779413</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate safety effectiveness patient age group exclude less 12 month old infant diabetes mellitus routine clinical practice Korea .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Patients All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus Routine Clinical Practice Korea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Signed consent obtain studyrelated activity ( studyrelated activity procedure relate recording data accord protocol ) The decision initiate treatment commercially available Tresiba® FlexTouch® make patient/Legally Acceptable Representative ( LAR ) treat physician independently decision include patient study Male Female , Age least 12 month , time signing informed consent type 1 type 2 diabetes mellitus schedule start treatment Tresiba® FlexTouch® base clinical judgment treat physician specify KoreanPrescribing Information ( KPI ) Previous participation study . Participation define give informed consent study Patients previously treat Tresiba® FlexTouch® Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . However , paediatric patient enrol patient 's primary caregiver ( e.g . parent ) legally acceptable representative ( LAR ) capable give study specific sign informed consent . Any chronic disorder severe disease opinion investigator might jeopardise patient 's safety compliance protocol Female pregnant , breastfeed intend become pregnant childbaring potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>